Immunotherapy Archives

Infographics 10 Jan 2018

Infographic: All You Need to Know About Checkpoint Inhibitors

Everything you need to know about what checkpoint inhibitors are and why they have caused a wave of hype for cancer immunotherapies. Since the approval of the first PD-1 checkpoint inhibitor, Keytruda, in 2014, there has been an explosion of the numbers of trials testing these drugs, both alone and in combination. The latest figure, […]

January 10, 2018 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 4 Jan 2018

German Biotech Raises Record $270M Series A for Individualized Cancer Therapies

BioNTech will dedicate its huge fundraising to develop personalized cancer immunotherapies using CAR-T, TCR and mRNA technologies. BioNTech is kicking off the new year with great news. The company has closed its Series A with $270M (€225M) — a record amount in Germany for such an early funding round. The fundraising was led by the […]

January 4, 2018 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 20 Dec 2017

Actelion Spin Out and Roche Join Forces to Develop Cancer Immunotherapies

Idorsia and Roche have agreed on a research collaboration, with the big pharma getting exclusive rights to develop and license resultant cancer immunotherapy drugs. Idorsia was formed out of J&J’s acquisition of Actelion for €27.9B at the beginning of the year. The spin out, led by Jean-Paul and Martine Clozel, kept hold of Actelion’s drug discovery and early […]

December 20, 2017 - 2 minutesmins - By Alex Dale

hpv cancer isa pharmaceuticals regeneron

News and Trends 18 Dec 2017

Dutch and US Biotechs Team Up Against HPV-related Cancer

ISA Pharmaceuticals will work together with Regeneron to combine its immunotherapy against cancer induced by HPV infection with its partner’s PD-1 checkpoint inhibitor. The human papillomavirus (HPV) is known for its ability to cause cancer, including cervical and head and neck cancer. Based in Leiden, the Netherlands, ISA Pharmaceuticals’ target choice is type 16 HPV, which […]

December 18, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 13 Dec 2017

Off-the-Shelf CAR-T Cells Struggle to Improve Cancer Treatment

Data presented at ASH 2017 shows that Servier and Pfizer’s UCART19, an allogeneic CAR-T therapy originally developed by Cellectis, might struggle to outperform autologous CAR-T cells. CAR-T cell therapy has proved to be effective at treating cancer in patients for whom scarce hope was left. Yet pricing is still a big concern. Companies like Cellectis are trying […]

December 13, 2017 - 4 minutesmins - By Clara Rodríguez Fernández

News and Trends 12 Dec 2017

Immunotherapy for Uveal Melanoma is on Track for Early Access in the UK

The UK grants Immunocore access to a fast-track scheme that will make its immunotherapy IMCgp100 available to patients with uveal melanoma before approval. The UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) has deemed Immunocore’s technology worth being used by patients before it’s approved. The regulatory agency has granted Promising Innovative Medicines (PIM) designation to IMCgp100 for […]

December 12, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 29 Nov 2017

Merck and Pfizer’s Checkpoint Inhibitor Fails to Treat Gastric Cancer

Avelumab, marketed as Bavencio by Pfizer and Merck, has failed to show better efficacy than chemotherapy in a Phase III trial with gastric cancer patients. Merck (the German one) and Pfizer joined the checkpoint inhibitor club earlier this year with the approval of Bavencio (avelumab) in both the US and Europe. Looking to keep expanding the […]

November 29, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 29 Nov 2017

One Mouse with All-Human Antibodies

Monoclonal antibodies have long been the focus of research surrounding drug development against inflammatory diseases and cancer. For decades, researchers have had to travel along a strenuous path to get to where we are now. After monoclonal antibodies (mAb) were discovered in the first half of the 20th century, researchers quickly understood that animals, such […]

November 29, 2017 - 6 minutesmins - By External Contributor

imcyse type 1 diabetes immunotherapy cure

News and Trends 15 Nov 2017

Update: Belgian Biotech Starts Human Trials for a Potential Type 1 Diabetes Cure

Update (15/11/2017): Imcyse has officially started recruiting patients to test its therapy for type 1 diabetes. The clinical trial will recruit up to 40 patients across 15 European centers, and the first patient has already enrolled at the Steno Diabetes Center in Copenhagen. Originally published on 30/05/2017 Imcyse will run its first clinical trial testing […]

November 15, 2017 - 3 minutesmins - By Clara Rodríguez Fernández

News and Trends 14 Nov 2017

This British Biotech Could Treat T-Cell Lymphoma without Leaving the Body Unprotected

Autolus has revealed a new strategy to treat T-cell lymphoma without harming healthy, protective T cells. The therapy is expected to start human tests soon. T-cell lymphoma is a form of cancer that affects the cells responsible for protecting our body against infections. Unlike it’s done with cancer types that affect other blood cells, it’s […]

November 14, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

tusk therapeutics cancer CD38 immunotherapy 1

News and Trends 14 Nov 2017

British Biotech Gets a £2.5M Grant to Boost Cancer Immunotherapy

Tusk Therapeutics is working on immunotherapies to ignite the immune system against cancer. The £2.5M grant will help it to accelerate their development. Tusk Therapeutics focuses on immuno-oncology to ‘harness the power’ of the immune system. One of its candidates is an antibody that targets the CD38 immune checkpoint, which is a marker of cell activation that […]

November 14, 2017 - 2 minutesmins - By Alex Dale

News and Trends 13 Nov 2017

Biotech Unicorn’s T-Cell Receptor Therapy “Nearly Doubles” Survival in Uveal Melanoma

Immunocore, one of the only three European biotech unicorns, has presented Phase I results for its TCR immunotherapy IMCgp100 in patients suffering from metastatic uveal melanoma. Results are positive, but perhaps not to the level of expectation for a company with such a high valuation. On Saturday, Immunocore presented its latest clinical results at the Society […]

November 13, 2017 - 3 minutesmins - By Clara Rodríguez Fernández

Knowledge hub

Categories

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Immunotherapy

Infographic: All You Need to Know About Checkpoint Inhibitors

German Biotech Raises Record $270M Series A for Individualized Cancer Therapies

Actelion Spin Out and Roche Join Forces to Develop Cancer Immunotherapies

Dutch and US Biotechs Team Up Against HPV-related Cancer

Off-the-Shelf CAR-T Cells Struggle to Improve Cancer Treatment

Immunotherapy for Uveal Melanoma is on Track for Early Access in the UK

Merck and Pfizer’s Checkpoint Inhibitor Fails to Treat Gastric Cancer

One Mouse with All-Human Antibodies

Update: Belgian Biotech Starts Human Trials for a Potential Type 1 Diabetes Cure

This British Biotech Could Treat T-Cell Lymphoma without Leaving the Body Unprotected

British Biotech Gets a £2.5M Grant to Boost Cancer Immunotherapy

Biotech Unicorn’s T-Cell Receptor Therapy “Nearly Doubles” Survival in Uveal Melanoma

Subscribe to our newsletter to get the latest biotech news!

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!